Compare InMode Ltd (INMD) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Merck & Co., Inc. — how do they compare? InMode Ltd trades at $15.36 (market cap $882.90M), while Merck & Co., Inc. trades at $125.41 (market cap $307.25B). The key difference: Merck & Co., Inc. is far larger — about 348× InMode Ltd's market cap, and Merck & Co., Inc. pays a 2.73% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| INMD | MRK | |
|---|---|---|
Market Cap | $882.90M | $307.25B |
Sector | Technology | Health |
52-Week High | $16.62 | $129.52 |
52-Week Low | $12.76 | $77.60 |
Enterprise Value | $350.57M | $350.66B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $15.36, down 0.71% on the day, with a bullish technical signal from moving averages but a neutral reading from oscillators. The company maintains strong profitability with a 77.84% gross margin and 23.27% net margin, though Q1 2026 earnings missed expectations. Recent news includes an unsolicited acquisition offer of $16.75 per share from Steel Partners and upcoming Q2 2026 results on August 5, 2026.
The stock presents a mixed outlook: attractive valuation multiples and a solid balance sheet support upside, but risks include earnings volatility, shareholder activism, and a securities fraud investigation. Analyst consensus is a $16.50 price target with a balanced buy/hold rating split, suggesting cautious optimism near-term.
Merck (MRK) trades at $125.25, down 1.76% on the day, with a neutral technical signal. The company reported strong earnings beats in recent quarters, with Q1 2026 results surpassing expectations. Fundamentals show robust profitability with a 73.91% gross margin and 13.59% net margin, though valuations are elevated with a P/E of 35.04. Recent news highlights the company's strategic acquisition of Terns Pharmaceuticals to bolster its oncology pipeline.
The outlook is supported by a strong analyst consensus with a $137.30 price target and 68% buy ratings, but risks include high valuation multiples, competitive pressures in oncology, and significant capital expenditure for pipeline development as indicated by negative investing cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
